Microbix Launches New Products to Support H3N2 Flu Testing

Core Insights - Microbix Biosystems Inc. has launched QAPs™ quality assessment products and QUANTDx™ reference materials to support testing for H3N2 strains of seasonal Influenza A [1] Group 1: Product Launch and Features - The new QAPs™ are designed to assist in the detection of H3N2 variants, which are becoming dominant in the 2025/26 Flu season, and are crucial for accurate disease management [3][4] - Microbix's QAPs provide multi-year room-temperature stability and are available in PROCEEDx® (RUO) and REDx® (IVD) variants, catering to different user needs [4] - QUANTDx products are characterized as accurately-quantified and fully-traceable reference materials that help assay developers establish key analytical performance metrics [5] Group 2: Company Overview - Microbix Biosystems Inc. reported revenues of C$ 25.4 million in its latest fiscal year (2024) and employs over 120 skilled personnel [7] - The company specializes in creating biological products for human health, including antigens for immunoassays and laboratory quality assessment products [7] - Microbix's QAPs are now available in over 30 countries, supported by a network of international distributors, and the company holds various accreditations including ISO 9001 & 13485 [7][8]